Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

L Rothenberg

Showing results (71-80 of 162) with videos related to

Pageof 17
Sort By:
The American Journal of Pathology|July 1, 1995
Tumor angiogenesis in advanced stage ovarian carcinomaH C Hollingsworth, E C Kohn, S M Steinberg, et al.
The Journal of Clinical Investigation|November 1, 1992
Regulation of insulin receptor substrate-1 in liver and muscle of animal models of insulin resistanceM J Saad, E Araki, M Miralpeix, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1992
Dose-intensive induction therapy with cyclophosphamide, cisplatin, and consolidative abdominal radiation in advanced-stage epithelial ovarian cancerM L Rothenberg, R F Ozols, E Glatstein, et al.
Diabetes|July 1, 1996
Wortmannin inhibits insulin secretion in pancreatic islets and beta-TC3 cells independent of its inhibition of phosphatidylinositol 3-kinaseZ Gao, R J Konrad, H Collins, et al.
Journal of the National Cancer Institute|November 16, 1988
High-dose carboplatin with diethyldithiocarbamate chemoprotection in treatment of women with relapsed ovarian cancerM L Rothenberg, Y Ostchega, S M Steinberg, et al.
Cancer|April 3, 1999
An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinomaA M Storniolo, N H Enas, C A Brown, et al.
Investigational New Drugs|January 1, 1997
Phase II study of flutamide as second line chemotherapy in patients with advanced pancreatic cancerJ J Sharma, B Razvillas, C D Stephens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 22, 2006
Pretreatment CA-125 and risk of relapse in advanced ovarian cancerMaurie Markman, P Y Liu, Mace L Rothenberg, et al.
Cancer|August 1, 1996
A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinomaM L Rothenberg, J L Abbruzzese, M Moore, et al.
Molecular Cancer Therapeutics|February 17, 2005
Silatecan DB-67 is a novel DNA topoisomerase I-targeted radiation sensitizerAllan Y Chen, Shyh-Jen Shih, Liza N Garriques, et al.
Pageof 17

Showing results (71-80 of 162) with videos related to

Sort By:
Pageof 17
The American Journal of Pathology|July 1, 1995
Tumor angiogenesis in advanced stage ovarian carcinomaH C Hollingsworth, E C Kohn, S M Steinberg, et al.
The Journal of Clinical Investigation|November 1, 1992
Regulation of insulin receptor substrate-1 in liver and muscle of animal models of insulin resistanceM J Saad, E Araki, M Miralpeix, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1992
Dose-intensive induction therapy with cyclophosphamide, cisplatin, and consolidative abdominal radiation in advanced-stage epithelial ovarian cancerM L Rothenberg, R F Ozols, E Glatstein, et al.
Diabetes|July 1, 1996
Wortmannin inhibits insulin secretion in pancreatic islets and beta-TC3 cells independent of its inhibition of phosphatidylinositol 3-kinaseZ Gao, R J Konrad, H Collins, et al.
Journal of the National Cancer Institute|November 16, 1988
High-dose carboplatin with diethyldithiocarbamate chemoprotection in treatment of women with relapsed ovarian cancerM L Rothenberg, Y Ostchega, S M Steinberg, et al.
Cancer|April 3, 1999
An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinomaA M Storniolo, N H Enas, C A Brown, et al.
Investigational New Drugs|January 1, 1997
Phase II study of flutamide as second line chemotherapy in patients with advanced pancreatic cancerJ J Sharma, B Razvillas, C D Stephens, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 22, 2006
Pretreatment CA-125 and risk of relapse in advanced ovarian cancerMaurie Markman, P Y Liu, Mace L Rothenberg, et al.
Cancer|August 1, 1996
A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinomaM L Rothenberg, J L Abbruzzese, M Moore, et al.
Molecular Cancer Therapeutics|February 17, 2005
Silatecan DB-67 is a novel DNA topoisomerase I-targeted radiation sensitizerAllan Y Chen, Shyh-Jen Shih, Liza N Garriques, et al.
Pageof 17